Wegovy vs Zepbound: Two Separate FDA-Approved Medications

They are different molecules from different manufacturers, both FDA-approved for chronic weight management. Wegovy contains semaglutide, which acts on the GLP-1 receptor; Zepbound contains tirzepatide, which acts on both the GIP and GLP-1 receptors. Which one is appropriate for a given person is a clinical decision made by a licensed provider based on their individual medical profile.

Both medications have similar gastrointestinal side effect profiles (nausea, diarrhea, constipation). Safety and suitability for any individual depend on that person's medical history and are evaluated by a licensed provider. Weight Method dispenses neither brand-name product.

Brand-name Zepbound® (tirzepatide) and brand-name Wegovy® (semaglutide) are different molecules made by different manufacturers (Eli Lilly and Novo Nordisk). Weight Method does not dispense or prescribe brand-name Zepbound® or Wegovy®. Weight Method's compounded tirzepatide program is $329/mo and compounded semaglutide program is $154/mo, dispensed by U.S.-licensed 503A compounding pharmacies. Compounded medications are not FDA-approved.

Any change between medications should occur under medical supervision, and Weight Method dispenses neither brand-name product. Whether a transition is appropriate and how dosing is managed is determined by a licensed provider based on your individual medical profile.

Eligibility for weight management treatment is based on clinical criteria such as BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Weight Method's online assessment evaluates your eligibility based on these criteria, and a licensed provider makes the final determination.